The nature and extent of voluntary intellectual capital disclosures by Australian and UK biotechnology companies

Abstract

Purpose

The purpose of this research project is to compare the nature and extent of voluntary intellectual capital disclosures (ICD) by UK and Australian biotechnology companies. The motivating research question was whether the nature and extent of voluntary ICD by preparers of financial report data in these countries reflected the relative maturity of the UK, compared to Australian industry.

Design/methodology/approach

ICD was measured in annual reports and financial statements published on the company websites. A Danish disclosure index was used to evaluate voluntary disclosures by 156 companies about customers, employees, IT, strategy, R&D and processes (78‐items scored for each company).

Findings

A significant leverage effect was demonstrated in relation to the “nature” of ICD by UK and Australian biotechnology companies. Interestingly, mean customer ICD were higher in annual reports from high‐leveraged compared to low‐leveraged Australian firms. In contrast, UK firms showed higher mean R&D ICD for low‐leveraged firms than high‐leveraged firms. With regards to the “extent” of ICD measured, the study demonstrated a significant country effect.

Research limitations/implications

Potential limitations or bias may exist from the use of the disclosure index: binary scoring of disclosure versus non‐disclosure reduces the richness of data otherwise obtainable by limited case study or interviews; and data collection is limiting – narrative with managers actually preparing ICD is not possible.

Practical implications

Australian company financial accountants and managers preparing and/or including ICD information could be in danger of underestimating the importance of information asymmetry existing with lenders.

Originality/value

This finding contrasts the legitimate R&D focused ICD of low‐leveraged UK firms; namely to attract stakeholder attention to their expanding intellectual property base, with the findings from Australian firms' with a relatively predictable and naïve customer focus.

Citation

White, G., Lee, A., Yuningsih, Y., Nielsen, C. and Nikolaj Bukh, P. (2010), "The nature and extent of voluntary intellectual capital disclosures by Australian and UK biotechnology companies", Journal of Intellectual Capital, Vol. 11 No. 4, pp. 519-536. https://doi.org/10.1108/14691931011085669